Corporate Profile
Barr
Pharmaceuticals, Inc. is a Delaware holding company whose principal
subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals,
Inc., develop, manufacture and market generic and proprietary
pharmaceutical products, respectively. The Company’s generic
products are marketed under the “Barr” label, and
proprietary products are marketed under the “Duramed”
label.
For the fiscal year ended June 30, 2006, the Company recorded net earnings of $337 million on revenues of $1.3 billion. Of the $1.3 billion of revenues in fiscal 2006, $839 million were from sales of generic products, $330 million were from sales of proprietary products, and $146 million were attributed to revenues derived from co-promotion alliances, development agreements and other sources.
Barr’s
business has two reportable segments: generic pharmaceuticals
and proprietary pharmaceuticals. In the generic pharmaceutical segment, the Company currently manufactures and distributes approximately 150 different dosage forms and strengths of approximately 75 different generic pharmaceutical products, including 22 oral contraceptive products, representing the largest category of the generic product portfolio.
In the
proprietary pharmaceutical segment, the Company currently manufactures
and distributes 19 proprietary pharmaceutical products, largely
concentrated in the female healthcare arena. These products include the SEASONIQUE™ (levonorgestrel and ethinyl estradiol) extended-cycle oral contraceptive product, ENJUVIA™ (synthetic conjugated estrogens, B) line of hormone therapy products, Plan B® emergency contraceptive (levonorgestrel) product, the ParaGard® T 380A Intrauterine Copper Contraceptive product, and Mircette® oral contraceptive.
Barr operates
manufacturing, research and development and administrative facilities
that are located in eight locations within the United States.
Executive offices are located in Woodcliff Lake, New Jersey.
Business
Strategies
The Company focuses its resources on three principal strategies:
•
developing and marketing selected generic pharmaceuticals;
•
developing and marketing proprietary pharmaceuticals; and
•
pursuing development and marketing of generic biopharmaceuticals.
Investment in Research and Development
The Company’s commitment to research and development, including acquired in-process research and development, resulted in investments of $128 million in fiscal 2005 and $140 million in fiscal 2006.
We have consistently
made these significant investments because of our belief that
a broad portfolio of products in development is critical to
our long-term success.
Research
and development expenditures for generic development activities
typically include those related to internal personnel, third-party
bioequivalence studies, costs paid to third-party development
partners and costs for raw materials used in developing products.
Proprietary
development costs typically include those related to internal
personnel, clinical studies, third-party toxicology studies,
clinical trials conducted by third-party clinical research organizations,
and raw materials.
The Company expects to continue to invest aggressively in research and development projects in 2007 and beyond.
Pursuing Development and Marketing of Generic Biopharmaceuticals
The Company is actively pursuing those business development
initiatives and internal development activities that will enable
it to bring generic versions of biopharmaceutical products to
market and intends to build a leadership position in the development
and marketing of such products in the future.
Corporate Development
To supplement internal efforts in support of its business strategies,
the Company continually evaluates business development opportunities
that it believes will strengthen our product portfolio and help
grow both our generic and proprietary businesses. The Company
regularly evaluates opportunities, particularly in the areas
of strategic product acquisitions and/or corporate mergers and
acquisitions. It also evaluates partnership arrangements that
may involve: new technology platforms on which to expand our
barrier to entry generic strategy, women’s healthcare
products in late stage development, and products or companies
for a new, second proprietary therapeutic category. As Barr
continues its growth strategy, the Company expects that business
development activities, including product and company acquisitions
will continue to increase.
Product Guide 
